Background: Endothelial progenitor cells (EPCs), which are positive for CD34, are considered to originate from hematopoietic stem cells. At present, the level of circulating EPCs (cEPCs) not only correlates with cumulative cardiovascular risk and vascular function but also predicts future cardiovascular events and atherosclerotic disease progression in patients with coronary artery disease (CAD). Several clinical and recently basic studies have suggested an extra-beneficial effect of the statins in the prevention of atherosclerosis and coronary artery disease. These studies showed that statins may affect the cardiovascular system beyond their effect on the lipid profile, and it was suggested that they affect the immunological system and vascular inflammation. Aim: The aim of the present study was to assess the impact of statin therapy on number and function of EPCs in patients with coronary artery disease and to assess the effect of statin on endothelial function estimated by brachial artery flow mediated dilatation. Methods: For all subjects, EPCs counted by Flow Cytometry. EPCs functions assessed by VEGFR2 and VWF gene expression by QRTPCR and eNOS protein assessment by ELISA. Flow mediated Doppler was done for all subjects. Results: There was statistical significant difference among the studied groups as regards EPCs count , functions and FMD percentage in patients on statins treatment compared to patients not on statins treatment.